Natural history study in adult patients with SMA types 2-3-4 and Role of neurodegenerative and neuro-inflammatory biomarkers in SMA adults treated with nusinersen
Latest Information Update: 10 Apr 2023
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
- 10 Apr 2023 Status changed from recruiting to completed.
- 08 Aug 2022 New source identified and integrated (European Clinical Trials Database: EudraCT2019-005007-40).
- 04 Aug 2022 Status changed to recruiting.